NDAORALCAPSULE, EXTENDED RELEASE
Approved
Mar 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
QUDEXY XR (topiramate) by Johnson & Johnson is cytochrome p450 3a4 inducers [moa]. Approved for epilepsy, migraine, seizures and 1 more indications. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUDEXY XR is an extended-release oral capsule formulation of topiramate, a cytochrome P450 3A4 inducer approved in 2014. It treats 19 conditions spanning epilepsy, migraine, obesity, diabetes, bipolar disorder, and substance use disorders. The mechanism involves enzyme induction that modulates multiple neurological and metabolic pathways.
$0.001BPart D
Peak6.9 years to LOEProduct is at peak lifecycle with minimal Part D penetration ($1M, 800 claims in 2023), suggesting mature market with limited growth opportunity and smaller commercial teams.
Mechanism of Action
Cytochrome P450 3A4 Inducers
Indications (4)
Worked on QUDEXY XR at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.